CL2012001671A1 - Compuestos derivados de (metilsulfonil)-etil-bencenoisoindolina; composicion farmaceutica que los comprende, uso en el tratamiento del cancer, dolor, trastornos del snc, enfermedades dermatologicas, entre otras. - Google Patents
Compuestos derivados de (metilsulfonil)-etil-bencenoisoindolina; composicion farmaceutica que los comprende, uso en el tratamiento del cancer, dolor, trastornos del snc, enfermedades dermatologicas, entre otras.Info
- Publication number
- CL2012001671A1 CL2012001671A1 CL2012001671A CL2012001671A CL2012001671A1 CL 2012001671 A1 CL2012001671 A1 CL 2012001671A1 CL 2012001671 A CL2012001671 A CL 2012001671A CL 2012001671 A CL2012001671 A CL 2012001671A CL 2012001671 A1 CL2012001671 A1 CL 2012001671A1
- Authority
- CL
- Chile
- Prior art keywords
- methylsulfonyl
- pain
- ethyl
- pharmaceutical composition
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Compuestos derivados de (metilsulfonil)-etil-benceno-isoindolina; composición farmacéutica que los comprende, útil para tratar el cáncer, dolor, una enfermedad de la piel, trastornos del SNC, aterosclerosis o un trastorno relacionado con tnfalfa.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28935609P | 2009-12-22 | 2009-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2012001671A1 true CL2012001671A1 (es) | 2012-11-23 |
Family
ID=43528318
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2012001671A CL2012001671A1 (es) | 2009-12-22 | 2012-06-20 | Compuestos derivados de (metilsulfonil)-etil-bencenoisoindolina; composicion farmaceutica que los comprende, uso en el tratamiento del cancer, dolor, trastornos del snc, enfermedades dermatologicas, entre otras. |
Country Status (17)
Country | Link |
---|---|
US (1) | US8716252B2 (es) |
EP (1) | EP2516395A1 (es) |
JP (1) | JP5760008B2 (es) |
KR (1) | KR20120113219A (es) |
CN (1) | CN102770412A (es) |
AU (1) | AU2010333767A1 (es) |
BR (1) | BR112012015129A2 (es) |
CA (1) | CA2783616A1 (es) |
CL (1) | CL2012001671A1 (es) |
CO (1) | CO6640204A2 (es) |
CR (1) | CR20120335A (es) |
EC (1) | ECSP12011987A (es) |
MX (1) | MX2012007217A (es) |
RU (1) | RU2012131164A (es) |
SG (1) | SG181891A1 (es) |
WO (1) | WO2011079091A1 (es) |
ZA (1) | ZA201203944B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2012236655B2 (en) | 2011-03-28 | 2016-09-22 | Deuterx, Llc, | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
CA2935495C (en) | 2013-01-14 | 2021-04-20 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
EP2968334A4 (en) | 2013-03-14 | 2016-08-03 | Deuterx Llc | 3- (SUBSTITIERTES-4-OXO-quinazolin-3 (4H) -yl) -3-deutero-PIPERIDINE-2,6-DIONE DERIVATIVES |
US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
RU2731095C2 (ru) | 2016-03-17 | 2020-08-28 | Ф. Хоффманн-Ля Рош Аг | Производное 5-этил-4-метил-пиразол-3-карбоксамида, обладающее активностью агониста taar |
US20190008837A1 (en) * | 2016-12-15 | 2019-01-10 | University Of Utah Research Foundation | Ophthalmic compositions and associated methods |
WO2020036386A1 (ko) * | 2018-08-16 | 2020-02-20 | 한국화학연구원 | 이소인돌린-1온 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 |
WO2021060567A1 (en) * | 2019-09-27 | 2021-04-01 | Takeda Pharmaceutical Company Limited | 2-isoindol-1,3,4-oxadiazole derivatives useful as hdac6 inhibitors |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
WO1995003009A1 (en) | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
US5770589A (en) | 1993-07-27 | 1998-06-23 | The University Of Sydney | Treatment of macular degeneration |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
IT1274549B (it) | 1995-05-23 | 1997-07-17 | Indena Spa | Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno |
US5728844A (en) * | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic agents |
US5800819A (en) | 1996-01-25 | 1998-09-01 | National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology | Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease |
HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
DE69740140D1 (de) | 1996-07-24 | 2011-04-14 | Celgene Corp | Substituierte 2-(2,6-Dioxopiperidin-3-yl)-phthalimide und Oxoisoindoline und Verfahren zur Verringerung der TNF-Alpha-Stufen |
US6015803A (en) | 1998-05-04 | 2000-01-18 | Wirostko; Emil | Antibiotic treatment of age-related macular degeneration |
US6225348B1 (en) | 1998-08-20 | 2001-05-01 | Alfred W. Paulsen | Method of treating macular degeneration with a prostaglandin derivative |
US6001368A (en) | 1998-09-03 | 1999-12-14 | Protein Technologies International, Inc. | Method for inhibiting or reducing the risk of macular degeneration |
US6667316B1 (en) * | 1999-11-12 | 2003-12-23 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
US7182953B2 (en) | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
CN1511420A (zh) | 2001-11-09 | 2004-07-07 | 松下电器产业株式会社 | 运动图像编码方法和装置 |
US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
US20050203142A1 (en) | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
US20040091455A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
US20050100529A1 (en) | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
MXPA06006061A (es) | 2003-12-02 | 2006-08-11 | Celgene Corp | Metodos y composiciones para el tratamiento y manejo de la hemoglinopatia y la anemia. |
US20050143344A1 (en) | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
EP1737453A4 (en) | 2004-03-22 | 2008-11-26 | Celgene Corp | METHOD FOR THE USE OF IMMUNOMODULATORY COMPOUNDS AND COMPOSITIONS CONTAINING THEREOF FOR THE TREATMENT AND SUPPLY OF SKIN DISEASES OR DISORDERS |
US20050222209A1 (en) | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
AU2005237490A1 (en) | 2004-04-23 | 2005-11-10 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension |
WO2006053160A2 (en) | 2004-11-12 | 2006-05-18 | Celgene Corporation | Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases |
CN101102771A (zh) | 2004-11-23 | 2008-01-09 | 细胞基因公司 | 用免疫调节化合物治疗和控制中枢神经系统损伤的方法和组合物 |
JP5775245B2 (ja) | 2004-12-01 | 2015-09-09 | セルジーン コーポレイション | 免疫不全障害の治療のために免疫調節化合物を用いる方法及び組成物 |
DE602006020300D1 (de) | 2005-09-01 | 2011-04-07 | Celgene Corp | Immunologische verwendungen von immunmodulatorischen verbindungen für einen impfstoff und therapie gegen infektionskrankheiten |
US8779132B2 (en) * | 2006-10-12 | 2014-07-15 | Astex Therapeutics Limited | Pharmaceutical compounds |
-
2010
- 2010-12-21 EP EP10801055A patent/EP2516395A1/en not_active Withdrawn
- 2010-12-21 CA CA2783616A patent/CA2783616A1/en not_active Abandoned
- 2010-12-21 BR BR112012015129A patent/BR112012015129A2/pt not_active IP Right Cessation
- 2010-12-21 RU RU2012131164/04A patent/RU2012131164A/ru not_active Application Discontinuation
- 2010-12-21 WO PCT/US2010/061420 patent/WO2011079091A1/en active Application Filing
- 2010-12-21 JP JP2012546129A patent/JP5760008B2/ja not_active Expired - Fee Related
- 2010-12-21 CN CN2010800645105A patent/CN102770412A/zh active Pending
- 2010-12-21 US US13/518,843 patent/US8716252B2/en active Active
- 2010-12-21 MX MX2012007217A patent/MX2012007217A/es active IP Right Grant
- 2010-12-21 AU AU2010333767A patent/AU2010333767A1/en not_active Abandoned
- 2010-12-21 SG SG2012046553A patent/SG181891A1/en unknown
- 2010-12-21 KR KR1020127016076A patent/KR20120113219A/ko not_active Application Discontinuation
-
2012
- 2012-05-30 ZA ZA2012/03944A patent/ZA201203944B/en unknown
- 2012-06-20 EC ECSP12011987 patent/ECSP12011987A/es unknown
- 2012-06-20 CL CL2012001671A patent/CL2012001671A1/es unknown
- 2012-06-20 CR CR20120335A patent/CR20120335A/es not_active Application Discontinuation
- 2012-07-06 CO CO12113701A patent/CO6640204A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US8716252B2 (en) | 2014-05-06 |
SG181891A1 (en) | 2012-07-30 |
CO6640204A2 (es) | 2013-03-22 |
CA2783616A1 (en) | 2011-06-30 |
CR20120335A (es) | 2012-10-31 |
AU2010333767A1 (en) | 2012-07-05 |
JP2013515073A (ja) | 2013-05-02 |
ECSP12011987A (es) | 2012-09-28 |
RU2012131164A (ru) | 2014-01-27 |
CN102770412A (zh) | 2012-11-07 |
MX2012007217A (es) | 2012-07-10 |
BR112012015129A2 (pt) | 2019-09-24 |
EP2516395A1 (en) | 2012-10-31 |
KR20120113219A (ko) | 2012-10-12 |
JP5760008B2 (ja) | 2015-08-05 |
ZA201203944B (en) | 2013-08-28 |
WO2011079091A1 (en) | 2011-06-30 |
US20130116204A1 (en) | 2013-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2012001671A1 (es) | Compuestos derivados de (metilsulfonil)-etil-bencenoisoindolina; composicion farmaceutica que los comprende, uso en el tratamiento del cancer, dolor, trastornos del snc, enfermedades dermatologicas, entre otras. | |
CL2008002793A1 (es) | Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras | |
ECSP067021A (es) | Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar) | |
AR059390A1 (es) | Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopausicos | |
ECSP067019A (es) | Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar) | |
PA8772101A1 (es) | Imidazol-triazolopirimidinas sustituidas | |
GT200600297A (es) | Nuevos anticuerpos anti-madcam | |
CY1116927T1 (el) | Προφαρμακα της τετραϋδροκανναβινολης, συνθεσεις οι οποιες περιλαμβανουν προφαρμακα της τετραϋδροκανναβινολης και μεθοδοι χρησης των ιδιων | |
AR091876A1 (es) | Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas | |
AR050623A1 (es) | Metodo para el tratamiento del trastorno de hiperactividad de deficit de atencion | |
EA201300242A1 (ru) | Фармацевтические композиции, содержащие замещенные ациланилиды | |
UY29796A1 (es) | Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor | |
ES2422739T3 (es) | Composición para el diagnóstico, prevención o tratamiento de enfermedades relacionadas con células que expresan IL-8 o GRO-, que comprende MSC de UCB | |
HN2005000255A (es) | Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis | |
CR8778A (es) | Revestimientos de azucar y metodos para estos | |
UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
AR084691A1 (es) | Formulacion de uso topico para un inhibidor de jak y metodo para tratar trastorno de la piel | |
CL2011002766A1 (es) | Compuestos derivados de carboxamida, inhibidores de calpaina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas, alzahimer, dolor, entre otras. | |
MX2014002668A (es) | Tratamiento de enfermedades relacionadas con subunidades alfa de canales de sonido regulados por voltaje (scnxa) con moleculas pequeñas. | |
GT200500378A (es) | Macrolidos | |
CR20110599A (es) | Composiciones farmacéuticamente activas que comprenden moduladores de estrés oxidativo (osm), nuevas entidades químicas, composiciones y usos | |
ECSP13012573A (es) | 6-amino-nicotinamidas sustituidas como moduladores de KCNQ2/3 | |
HN2012000023A (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
CL2011002206A1 (es) | Compuestos derivados de benzofurano sustituidos, moduladores del señalador igf1 o activador de la proteina quinasa b; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades del snc, tales como alzheimer, entre otras. | |
CL2007002382A1 (es) | Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento del cancer a la piel. |